【市场】华海药业出手了，抢攻3亿降压药

米内网12-18

精彩内容12月18日，CDE官网显示，华海药业的4类仿制药培哚普利氨氯地平片(Ⅲ)上市申请获得承办。培哚普利氨氯地平片(Ⅲ)为复方降压药，2023年在中国三大终端六大市场销售额超过3亿元。培哚普利氨氯地平是由培哚普利（血管紧张素转换酶抑制剂）和氨氯地平（二氢吡啶类钙离子内流抑制剂）组成的复方制剂，用于单药治疗不能充分控制高血压的成人患者；或者作为替代疗法适用于在相同剂量水平的培哚普利和氨氯地平联合...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2492970006?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-12-18 17:02","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2492970006","market":"sh","top_or_hot":-1,"title":"【市场】华海药业出手了，抢攻3亿降压药","media":"米内网","content":"<div>\n<p>精彩内容12月18日，CDE官网显示，华海药业的4类仿制药培哚普利氨氯地平片(Ⅲ)上市申请获得承办。培哚普利氨氯地平片(Ⅲ)为复方降压药，2023年在中国三大终端六大市场销售额超过3亿元。培哚普利氨氯地平是由培哚普利（血管紧张素转换酶抑制剂）和氨氯地平（二氢吡啶类钙离子内流抑制剂）组成的复方制剂，用于单药治疗不能充分控制高血压的成人患者；或者作为替代疗法适用于在相同剂量水平的培哚普利和氨氯地平联合...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241218172613ab8170e2&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>【市场】华海药业出手了，抢攻3亿降压药</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n【市场】华海药业出手了，抢攻3亿降压药\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-18 17:02 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241218172613ab8170e2&s=b><strong>米内网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>精彩内容12月18日，CDE官网显示，华海药业的4类仿制药培哚普利氨氯地平片(Ⅲ)上市申请获得承办。培哚普利氨氯地平片(Ⅲ)为复方降压药，2023年在中国三大终端六大市场销售额超过3亿元。培哚普利氨氯地平是由培哚普利（血管紧张素转换酶抑制剂）和氨氯地平（二氢吡啶类钙离子内流抑制剂）组成的复方制剂，用于单药治疗不能充分控制高血压的成人患者；或者作为替代疗法适用于在相同剂量水平的培哚普利和氨氯地平联合...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241218172613ab8170e2&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0201","symbol_name":"可转债","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241218172613ab8170e2&s=b","article_id":"2492970006","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241218172613ab8170e2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2492970006","pubTimestamp":1734512570,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"精彩内容12月18日，CDE官网显示，华海药业的4类仿制药培哚普利氨氯地平片(Ⅲ)上市申请获得承办。培哚普利氨氯地平片(Ⅲ)为复方降压药，2023年在中国三大终端六大市场销售额超过3亿元。华海药业获批上市的高血压用药来源：米内网中国上市药品数据库","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600521":"华海药业","BK0201":"可转债","BK0028":"国家队","BK0012":"证金概念","BK0185":"二线龙头","BK0239":"医药制造","BK0070":"员工持股","BK0188":"融资融券"},"translate_title":"[Market] Huahai Pharmaceutical has taken action, rushing to attack 300 million antihypertensive drugs","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600521":1},"content_text":"精彩内容12月18日，CDE官网显示，华海药业的4类仿制药培哚普利氨氯地平片(Ⅲ)上市申请获得承办。培哚普利氨氯地平片(Ⅲ)为复方降压药，2023年在中国三大终端六大市场销售额超过3亿元。培哚普利氨氯地平是由培哚普利（血管紧张素转换酶抑制剂）和氨氯地平（二氢吡啶类钙离子内流抑制剂）组成的复方制剂，用于单药治疗不能充分控制高血压的成人患者；或者作为替代疗法适用于在相同剂量水平的培哚普利和氨氯地平联合治疗下病情得以控制的原发性高血压。米内网数据显示，施维雅的培哚普利氨氯地平片(Ⅲ)自上市以来，销售额一路飙升，2023年在中国三大终端六大市场（统计范围详见本文末）销售额超过3亿元，同比增长37.15%；2024年上半年销售额超过2亿元，同比增长9.55%。中国三大终端六大市场培哚普利氨氯地平片(Ⅲ)销售情况（单位：万元）来源：米内网格局数据库培哚普利氨氯地平片(Ⅲ)已纳入国家医保乙类目录，目前国内市场仅2家企业拥有该产品生产批文，其中原研厂家施维雅的培哚普利氨氯地平片(Ⅲ)于2018年5月获批进入国内市场，首仿厂家一品红的培哚普利氨氯地平片(Ⅲ)于2024年12月1日获批上市。华海药业获批上市的高血压用药来源：米内网中国上市药品（MID）数据库","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492970006"}